Tuberculosis Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Tuberculosis Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Tuberculosis
New tuberculosis study findings recently were published by researchers at University of California
June 15th, 2009
According to recent research from the United States, "The two front-line drugs for chronic Trypanosoma cruzi infections are limited by adverse side-effects and declining efficacy. One potential new target for Chagas' disease chemotherapy is sterol 14 alpha-demethylase (CYP51), a cytochrome P450 enzyme involved in biosynthesis of membrane sterols." "Methodology/Principal Finding: In a screening effort targeting Mycobacterium tuberculosis CYP51 (CYP51(Mt)), we previously identified the N-[4-pyridyl]-formamide moiety as a building block capable of delivering a variety of chemotypes into the CYP51 active site. In that work, the binding modes of several second generation...
Source: Tuberculosis Week (2009-06-15)
|
